Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00584857 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer
A Phase 2 study of Uterine Cancer, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00584857: Completed Phase 2 study of Uterine Cancer, sponsored by University of Alabama at Birmingham.
NCT00584857 is a Phase 2 study of Uterine Cancer that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 30 participants, below the 270-participant average among 27 other Uterine Cancer trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00584857, a Phase 2 study of Uterine Cancer, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study to determine the optimal treatment for patients with advanced stage or recurrent endometrial cancer. Traditionally, patients have been treated with either hormonal therapies (megesterol) or chemotherapy (paclitaxel and carboplatin). This study investigates the effectiveness of the combination of hormonal therapy and chemotherapy. This study also will examine the side-effects associated with these drugs and the quality of life of patients on combination therapy.
Primary Outcome
Number of subjects alive at 3 years
Conditions Studied
Interventions
- DRUG Paclitaxel ,Carboplatin , Megesterol Acetate
Study Locations (1)
Alabama
- UAB Women's and Infant Center, 1700 6th Ave S - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-07 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
What the finished NCT00584857 record still lists
NCT00584857 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 270-participant average among 27 other Uterine Cancer trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Uterine Cancer appearing as the primary indexed condition, and to 1 intervention - of which Paclitaxel ,Carboplatin , Megesterol Acetate is the first listed.
NCT00584857 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT00584857 about?
NCT00584857 is a clinical study titled "A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer". This is a study to determine the optimal treatment for patients with advanced stage or recurrent endometrial cancer. Traditionally, patients have been treated with either hormonal therapies (megesterol) or chemotherapy (paclitaxel and carboplatin). This study investigates the effectiveness of the co...
What is the current status of trial NCT00584857?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2004-07. Estimated completion is 2011-10.
What conditions does trial NCT00584857 study?
This clinical trial studies the following conditions: Uterine Cancer.
What interventions are being tested in trial NCT00584857?
The interventions under investigation include: Paclitaxel ,Carboplatin , Megesterol Acetate (DRUG).
Who is sponsoring clinical trial NCT00584857?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00584857 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uterine Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00584857's enrollment target sits among peer trials
30 18th of 27 higher than 7 of 27 other Uterine Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Uterine Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
RECRUITING · Phase 2
-
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
RECRUITING · Phase 2
-
[18F]FES PET/.CT in Uterine Cancer
RECRUITING · Phase 2
-
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
RECRUITING · Phase 2
-
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Nivolumab in Selected Uterine Cancer Patients
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia